EPCAM and cancer: Considering that cancer cells can escape immune surveillance by surface overexpression of CD47 and PD-L1, Shu et al. designed an epithelial cell adhesion molecule (EpCAM)-targeted cationic liposome with si-PD-L1 and si-CD47, which could actively target EpCAM overexpressing cancer cells and knockdown the PD-L1 and CD47 proteins.